Cargando…
SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases
Stereotactic radiosurgery provides effective local control, but high recurrence rate are observed while ipilimumab have shown promising improvements in survival in the treatment of melanoma brain metastases. This meta-analysis was done to review the clinical evidence regarding the combination of ste...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137552/ https://www.ncbi.nlm.nih.gov/pubmed/30213236 http://dx.doi.org/10.1177/1533033818798792 |
_version_ | 1783355199206719488 |
---|---|
author | Khan, Muhammad Lin, Jie Liao, Guixiang Tian, Yunhong Liang, Yingying Li, Rong Liu, Mengzhong Yuan, Yawei |
author_facet | Khan, Muhammad Lin, Jie Liao, Guixiang Tian, Yunhong Liang, Yingying Li, Rong Liu, Mengzhong Yuan, Yawei |
author_sort | Khan, Muhammad |
collection | PubMed |
description | Stereotactic radiosurgery provides effective local control, but high recurrence rate are observed while ipilimumab have shown promising improvements in survival in the treatment of melanoma brain metastases. This meta-analysis was done to review the clinical evidence regarding the combination of stereotactic radiosurgery and ipilimumab in the treatment of brain metastases from melanoma. Comprehensive research of the electronic databases (PubMed and Cochrane Library) was carried out in April 2017. Different combination of MESH headings and words were used. Review Manager was used to analyze the outcome data of interest. According to heterogeneity, fixed effects model or random effects model was adapted. Six retrospective studies comparing stereotactic radiosurgery plus ipilimumab with stereotactic radiosurgery alone were found. Total of 411 participants were included in this meta-analysis. Of that, 128 patients had received stereotactic radiosurgery + ipilimumab, while 283 patients had received stereotactic radiosurgery only. Stereotactic radiosurgery plus ipilimumab significantly improved survival when compared to stereotactic radiosurgery alone (hazard ratio: 0.74 [95% confidence interval: 0.56-0.99, P = .04]), with no significant increase in the incidence of adverse events (odds ratio 0.57 [95% confidence interval: 0.28-1.17, P = .12]). Stereotactic radiosurgery with ipilimumab is safe and effective treatment option and can be recommended for the treatment of brain metastases in patients with melanoma. |
format | Online Article Text |
id | pubmed-6137552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-61375522018-09-18 SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases Khan, Muhammad Lin, Jie Liao, Guixiang Tian, Yunhong Liang, Yingying Li, Rong Liu, Mengzhong Yuan, Yawei Technol Cancer Res Treat Review Stereotactic radiosurgery provides effective local control, but high recurrence rate are observed while ipilimumab have shown promising improvements in survival in the treatment of melanoma brain metastases. This meta-analysis was done to review the clinical evidence regarding the combination of stereotactic radiosurgery and ipilimumab in the treatment of brain metastases from melanoma. Comprehensive research of the electronic databases (PubMed and Cochrane Library) was carried out in April 2017. Different combination of MESH headings and words were used. Review Manager was used to analyze the outcome data of interest. According to heterogeneity, fixed effects model or random effects model was adapted. Six retrospective studies comparing stereotactic radiosurgery plus ipilimumab with stereotactic radiosurgery alone were found. Total of 411 participants were included in this meta-analysis. Of that, 128 patients had received stereotactic radiosurgery + ipilimumab, while 283 patients had received stereotactic radiosurgery only. Stereotactic radiosurgery plus ipilimumab significantly improved survival when compared to stereotactic radiosurgery alone (hazard ratio: 0.74 [95% confidence interval: 0.56-0.99, P = .04]), with no significant increase in the incidence of adverse events (odds ratio 0.57 [95% confidence interval: 0.28-1.17, P = .12]). Stereotactic radiosurgery with ipilimumab is safe and effective treatment option and can be recommended for the treatment of brain metastases in patients with melanoma. SAGE Publications 2018-09-13 /pmc/articles/PMC6137552/ /pubmed/30213236 http://dx.doi.org/10.1177/1533033818798792 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Khan, Muhammad Lin, Jie Liao, Guixiang Tian, Yunhong Liang, Yingying Li, Rong Liu, Mengzhong Yuan, Yawei SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases |
title | SRS in Combination With Ipilimumab: A Promising New Dimension for Treating
Melanoma Brain Metastases |
title_full | SRS in Combination With Ipilimumab: A Promising New Dimension for Treating
Melanoma Brain Metastases |
title_fullStr | SRS in Combination With Ipilimumab: A Promising New Dimension for Treating
Melanoma Brain Metastases |
title_full_unstemmed | SRS in Combination With Ipilimumab: A Promising New Dimension for Treating
Melanoma Brain Metastases |
title_short | SRS in Combination With Ipilimumab: A Promising New Dimension for Treating
Melanoma Brain Metastases |
title_sort | srs in combination with ipilimumab: a promising new dimension for treating
melanoma brain metastases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137552/ https://www.ncbi.nlm.nih.gov/pubmed/30213236 http://dx.doi.org/10.1177/1533033818798792 |
work_keys_str_mv | AT khanmuhammad srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases AT linjie srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases AT liaoguixiang srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases AT tianyunhong srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases AT liangyingying srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases AT lirong srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases AT liumengzhong srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases AT yuanyawei srsincombinationwithipilimumabapromisingnewdimensionfortreatingmelanomabrainmetastases |